Peter Sankey

481 total citations
9 papers, 252 citations indexed

About

Peter Sankey is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Peter Sankey has authored 9 papers receiving a total of 252 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in Peter Sankey's work include Cancer Immunotherapy and Biomarkers (4 papers), Prostate Cancer Treatment and Research (3 papers) and Economic and Financial Impacts of Cancer (2 papers). Peter Sankey is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Prostate Cancer Treatment and Research (3 papers) and Economic and Financial Impacts of Cancer (2 papers). Peter Sankey collaborates with scholars based in United Kingdom, United States and Australia. Peter Sankey's co-authors include Christopher McNair, Jack London, Matvey B. Palchuk, Elnara Fazio‐Eynullayeva, Debra H. Josephs, Daniel Poon, Simon J. Crabb, Robert H. Jones, Mark Linch and Leah Ensell and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Peter Sankey

7 papers receiving 248 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Sankey United Kingdom	5	230	55	53	41	26	9	252
Abdullah A. Alsharm Saudi Arabia	6	209 0.9×	46 0.8×	50 0.9×	41 1.0×	24 0.9×	18	307
Karlijn de Joode Netherlands	5	163 0.7×	32 0.6×	34 0.6×	15 0.4×	18 0.7×	23	203
Hagar Elghazawy Egypt	9	182 0.8×	60 1.1×	22 0.4×	14 0.3×	34 1.3×	19	284
Stuthi Perimbeti United States	8	108 0.5×	42 0.8×	41 0.8×	23 0.6×	18 0.7×	45	253
Justin Jee United States	9	252 1.1×	49 0.9×	30 0.6×	42 1.0×	44 1.7×	28	340
Elissar Moujaess Lebanon	6	226 1.0×	39 0.7×	19 0.4×	15 0.4×	35 1.3×	9	318
Patricia Villain France	9	250 1.1×	81 1.5×	32 0.6×	24 0.6×	21 0.8×	13	314
Amanda R. Kahl United States	10	167 0.7×	45 0.8×	27 0.5×	25 0.6×	16 0.6×	33	291
Perrine Vuagnat France	10	274 1.2×	96 1.7×	23 0.4×	21 0.5×	33 1.3×	34	388
Lucie de Jonge Netherlands	11	396 1.7×	132 2.4×	40 0.8×	37 0.9×	24 0.9×	32	429

Countries citing papers authored by Peter Sankey

Since Specialization

Citations

This map shows the geographic impact of Peter Sankey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Sankey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Sankey more than expected).

Fields of papers citing papers by Peter Sankey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Sankey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Sankey. The network helps show where Peter Sankey may publish in the future.

Co-authorship network of co-authors of Peter Sankey

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Sankey. A scholar is included among the top collaborators of Peter Sankey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Sankey. Peter Sankey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Linch, Mark, Gianmarco Leone, Yien Ning Sophia Wong, et al.. (2024). Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 5013–5013. 5 indexed citations

Bahl, Amit, Amarnath Challapalli, Alison Birtle, et al.. (2024). Multi-centre prospective evaluation of cognitive function in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) or enzalutamide (ENZ): The ACE study.. Journal of Clinical Oncology. 42(4_suppl). 20–20.

Azad, Arun, Mark Voskoboynik, Anthony M. Joshua, et al.. (2024). PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results.. Journal of Clinical Oncology. 42(4_suppl). 123–123. 6 indexed citations

Bridgewater, John, Saifee Mullamitha, Michael Braun, et al.. (2020). 502P Nivolumab, alone or with ipilimumab, for mismatch repair deficient metastatic colorectal cancer: A United Kingdom multicentre analysis of patient outcomes. Annals of Oncology. 31. S453–S453.

London, Jack, et al.. (2020). Abstract PO-040: The Effects of the COVID-19 pandemic on cancer patient encounters. Clinical Cancer Research. 26(18_Supplement). PO–40. 1 indexed citations

Poon, Daniel, Simon J. Crabb, Robert H. Jones, et al.. (2020). Immune checkpoint inhibitor induced large vessel vasculitis. BMJ Case Reports. 13(5). e233496–e233496. 13 indexed citations

Poon, Daniel, Simon J. Crabb, Robert H. Jones, et al.. (2020). Republished: Immune checkpoint inhibitor induced large vessel vasculitis. Drug and Therapeutics Bulletin. 59(2). 29–31. 1 indexed citations

London, Jack, Elnara Fazio‐Eynullayeva, Matvey B. Palchuk, Peter Sankey, & Christopher McNair. (2020). Effects of the COVID-19 Pandemic on Cancer-Related Patient Encounters. JCO Clinical Cancer Informatics. 4(4). 657–665. 221 indexed citations

Wong, Yien Ning Sophia, Peter Sankey, Debra H. Josephs, et al.. (2019). Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).. Journal of Clinical Oncology. 37(15_suppl). TPS5090–TPS5090. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact